Adding immunotherapy to chemotherapy may increase the risk of toxicity and likelihood of treatment discontinuation in patients with SCLC, a meta-analysis suggests.
Your search for non small cell lung cancer returned 7 results
Amivantamab can provide a long-term benefit in NSCLC patients with EGFR exon 20 insertions whose disease progressed on platinum-based chemotherapy, a study suggests.
Improvement seen compared with chemotherapy alone for first-line treatment of advanced non-small cell lung cancer.
Cancer patients with biomarker-positive tumors have better outcomes on immune checkpoint inhibitor therapy, a meta-analysis suggests.
A regulatory decision is expected on November 27, 2023.
Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody.
Reviewers discussed new and conventional therapies for lupus nephritis and the prospect of precision medicine.